The genetics and neuropathology of frontotemporal lobar degeneration

Anne Sieben · Tim Van Langenhove · Sebastiaan Engelborghs · Jean-Jacques Martin · Paul Boon · Patrick Cras · Peter-Paul De Deyn · Patrick Santens · Christine Van Broeckhoven · Marc Cruts

Abstract Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of disorders characterized by disturbances of behavior and personality and different types of language impairment with or without concomitant features of motor neuron disease or parkinsonism. FTLD is characterized by atrophy of the frontal and anterior temporal brain lobes. Detailed neuropathological studies have elicited proteinopathies defined by inclusions of hyperphosphorylated microtubule-associated protein tau, TAR DNA-binding protein TDP-43, fused-in-sarcoma or yet unidentified proteins in affected brain regions. Rather than the type of proteinopathy, the site of neurodegeneration correlates relatively well with the clinical presentation of FTLD. Molecular genetic studies identified five disease genes, of which the gene encoding the tau protein (MAPT), the growth factor precursor gene granulin (GRN), and C9orf72 with unknown function are most frequently mutated. Rare mutations were also identified in the genes encoding valosin-containing protein (VCP) and charged multivesicular body protein 2B (CHMP2B). These genes are good markers to distinguish underlying neuropathological phenotypes. Due to the complex landscape of FTLD diseases, combined characterization of clinical, imaging, biological and genetic biomarkers is essential to establish a detailed diagnosis. Although major progress has been made in FTLD research in recent years, further studies are needed to completely map out and correlate the clinical, pathological and genetic entities, and to understand the underlying disease mechanisms. In this review, we summarize the current state of the rapidly progressing field of genetic, neuropathological and clinical research of this intriguing condition.

Keywords Frontotemporal lobar degeneration · Proteinopathy · MAPT · GRN · C9orf72 · VCP · CHMP2B · Tau · TDP-43 · FUS

Introduction

History and significance

Frontotemporal lobar degeneration (FTLD) is an anatomopathological descriptive term referring to a disorder characterized by the relatively selective atrophy of the frontal and anterior temporal lobes of the brain. Apart from this commonality, FTLD is a clinically, genetically and
pathologically heterogeneous group of disorders. Because disease onset occurs before the age of 65 years in 75–80 % of the patients, FTLD is considered a presenile dementia [110, 122]. In the age group between 45 and 65 years, the prevalence of FTLD has been estimated between 10 and 30 per 100,000 [11, 136], but large-scale epidemiological studies are lacking. FTLD is the second most common form of early-onset dementia, after Alzheimer’s disease (AD) [19].

FTLD has a markedly strong familial component: 30–50 % of the FTLD patients report at least one relative with similar symptomatology, and in 10–23 %, the disease segregates in the family with an autosomal dominant inheritance pattern [56, 57]. Five disease genes have been identified to cause FTLD. Further, FTLD is associated with genes that typically cause a clinical picture of amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND). Common genetic, clinical and pathological characteristics between FTLD and ALS are manifold. In this era of rapidly evolving insights into the pathophysiology of this challenging group of diseases, the present review aims to provide a timely picture of the clinical, neuropathological and genetic findings in FTLD and the correlations between them.

Clinical phenotypes of FTLD and related conditions

FTLD can manifest as two clinically recognized subtypes based on the presenting and predominant features of either behavioral and personality changes, or language disturbances. The behavioral variant of frontotemporal dementia (bvFTD) is characterized by severe changes in behavior and personality such as disinhibition, apathy, loss of empathy, or stereotypic behavior, leading to a loss of social competence [73, 109, 127, 151]. Executive functions are impaired, while at least in the initial stages of the disease, memory and perceptuospatial skills are well preserved. As the differential diagnosis in patients with psychiatric disturbances or AD is not always straightforward, the ‘International Behavioral Variant FTD Criteria Consortium’ developed international consensus criteria for bvFTD. According to these criteria, subclassifications were made in possible bvFTD defined by clinical criteria, probable bvFTD supported by neuro-imaging data, and definite bvFTD confirmation by neuropathological evidence or a pathogenic mutation [127]. bvFTD accounts for more than 50 % of the FTLD patients. The onset of bvFTD is typically before the age of 65 years, with an average onset age of 58 years [71, 73].

If the patient presents with language difficulties, a diagnosis of primary progressive aphasia (PPA) is made. PPA was originally further categorized into progressive nonfluent aphasia (PNFA) and semantic dementia (SD) [73]. However, the clinical picture of a number of PPA patients did not fit either diagnosis, which led to the description of the third variant, logopenic progressive aphasia (LPA). The lack of clear definitions of the three subtypes led in 2011 to new recommendations for the subclassification of PPA into nonfluent/agrammatic variant PPA (the former PNFA), semantic variant PPA (the former SD) and the logopenic variant PPA (also known as LPA) [59]. Nonfluent/agrammatic variant PPA or PNFA is characterized by effortful speech and grammatical error-making, with relatively preserved language comprehension. Apraxia of speech (AOS) or orofacial apraxia is frequently accompanying the aphasia [73]. PNFA is the second most prevalent presentation of FTLD, accounting for a large 25 % [71]. Semantic variant PPA or SD presents with impaired comprehension and conceptual knowledge with concomitant development of anomia, while speech production is spared [59, 109, 151]. SD presents in 20–25 % of the FTLD patients [71]. LPA is mostly associated with a neuropathological diagnosis of AD [121] and is not considered part of the FTLD group of disorders. Based on the evidence supporting the diagnosis of PPA, the label “possible” (clinical features), “probable” (clinical findings in combination with neuro-imaging) and “definite” (after post-mortem examination or when a gene mutation is known) are provided [59, 125].

Overlap between the clinical syndromes of bvFTD, PNFA and SD can occur during the progression of the disease and clinical distinction between them is often complicated in advanced disease stages. The median survival from the onset of symptoms is 6–11 years, independent of age at onset or gender [63, 130]. While some studies show no differences in survival rates among the clinical subtypes of FTLD, other studies suggested shorter survival in bvFTD and longest survival in SD [63, 71, 115, 130]. The gender distribution of FTLD appears to vary by the clinical syndrome, with a male preponderance in the behavioral and personality disorders and a female predominance in the language disorders [71].

The comorbidity of ALS with behavior alterations, cognitive impairment or dementia has been noticed since the early 20th century [91, 119, 129]. FTLD may precede, follow or coincide with the onset of motor symptoms [172]. In one of the largest studies on neuropsychological disturbances in ALS, 47 % of the patients showed some degree of dysfunction in frontal lobe tests, which was in 15 % sufficient for a diagnosis of FTLD [129]. Conversely, motor neuron dysfunction has been described in 40 % of the FTLD patients, and the diagnostic criteria for ALS were met in 15 %, referred to as FTLD-ALS [18, 90]. FTLD-ALS patients have a poor prognosis with a mean survival of 2–3 years from the onset of first symptoms [63, 73]. The reported heritability of FTLD-ALS is high: approximately 50 % is considered familial [56, 132, 141].
Apart from MND, other conditions are closely related to FTLD, including progressive supranuclear palsy (PSP) syndromes, corticobasal syndrome (CBS), FTD with parkinsonism (FTDP) and argyrophilic grain disease (AGD). The most common clinical syndromes are PSP syndromes with a prevalence of 3.1 per 100,000, followed by CBS with a prevalence of less than 1 per 100,000 [41]. PSP was originally described as a clinical syndrome characterized by extrapyramidal symptoms and a progressive dementia. Patients present with a symmetrical, akinetic rigid parkinsonism, severe postural instability and supranuclear ophthalmoplegia. Most patients develop the disease at middle or late age (75 ± 8 years) and death occurs on average 7 years later [35]. In more recent years, the spectrum of PSP syndromes has been extended to not only include classical PSP syndrome, termed the Richardson’s type, but also PSP-parkinsonism, which presents as a more asymmetrical disorder resembling Parkinson’s disease [177] and the syndrome of pure akinesia characterized by freezing of gait and speech dysfluencies as most prominent features [34, 177]. CBS most frequently presents as a combined clinical picture, consisting of a focal cortical deficit (e.g. limb apraxia, aphasia, frontal lobe syndrome, alien limb phenomenon, cortical sensory loss) and a progressive asymmetrical movement disorder (myoclonus, dystonia, tremor). In a later stage of the disease, patients often develop cognitive dysfunctions, sometimes in combination with a frontaltemporal behavioral syndrome. The term FTDP-17 was defined in 1997 [47, 153], describing 13 families presenting with a clinical syndrome of autosomal dominant disinhibition, dementia, parkinsonism, and amyotrophy and showing genetic linkage to chromosome 17. Nowadays, we are able to differentiate mutations in the MAPT or to the GRN gene, both located on chromosome 17. The clinical picture resembles bvFTD, while cognitive deficits include anterograde memory dysfunction in an initial stage, later accompanied by progressive deterioration of visuospatial function, orientation and global memory. Eventually, mutism occurs. Motor signs typically include the development of symmetrical bradykinesia without resting tremor, in combination with axial rigidity and postural instability. There is poor or no effect of levodopa therapy. Other motor symptoms include vertical gaze palsy, dystonia, upper and lower motor dysfunction, eye lid apraxia and dysphagia [35]. The onset age can range from the early 20s to the late 70s, with an average of 50 years. The clinical early presentation of AGD is similar to AD but disease progression is less aggressive, with patients having a clinical picture resembling mild cognitive impairment (MCI) for many years [35, 44]. AGD accounts for approximately 5 % of the neurodegenerative dementia cases, with an increasing prevalence with advancing age [35, 44]. As FTLD is a distinctive clinical, genetic and neuropathological entity, it should be noted that an FTD phenotype can also be caused by underlying AD pathology (i.e. frontal variant AD). Similarly, a clinical phenotype of CBS can be caused by AD pathology [61].

Neuropathology of FTLD and cliniconeuropathological correlations

The FTLD brain is by definition characterized by diverse patterns of atrophy of frontal and anterior temporal lobes. Different patterns of atrophy have been described and a strong correlation with clinical phenotypes was found. A relatively symmetrical atrophy of the frontal lobes, insula, anterior cingulate and anterior temporal lobes is associated with bvFTD. An asymmetric atrophy of the left (linguistic dominant) anterior inferior temporal lobe gives rise to SD. Patients with an asymmetrical atrophy of the right anterior temporal lobe (right-sided SD) present with a behavioral syndrome similar to bvFTD. These patients develop emotional bluntness and, in some cases, loss of interest and bizarre affect. As the atrophy progresses, prosopagnosia and associativeagnosia are often seen in combination with eating disorders and rigid, compulsive behavior. In patients with PNFA, an asymmetric atrophy involving the anterior perisylvian cortex, mainly of the dominant hemisphere, is seen [59, 122].

On microscopic examination, the neuronal loss and astrocitosis are seen in cortices of atrophied frontal and temporal lobes. In addition, FTLD is a proteinopathy characterized by the presence of abnormal, ubiquitinated protein inclusions in cytoplasm or nuclei of neuronal and glial cells. Adjunctive immunohistochemistry allows subcategorization of these disorders into specific proteinopathies based on the major constituent of the inclusions. From a historic perspective, two pathological categories of FTLD were initially made [20, 95, 103]: in a first group of patients, the disease presented neurons and glial cells containing inclusions of hyperphosphorylated tau protein, therefore referred to as FTLD-tau [97], including Pick’s disease (PiD). However, more than 50 % of the FTLD patients presented with tau-negative ubiquitin staining inclusions at the time of unknown composition, therefore referred to as FTLD-Ubiquitin or FTLD-U [90, 95]. In 80–95 % [94, 131] of this group, inclusions were later found to be composed of transactive response (TAR) DNA-binding protein 43 (TDP-43) [111], thus referred to as FTLD-TDP [95, 112]. A considerable number of TDP-43-negative FTLD-U cases had inclusions of fused-in-sarcoma protein (FUS), thus referred to as FTLD-FUS [96]. However, in a small number of FTLD-U patients, the inclusion protein remains unknown until today. This group is referred to as FTLD-ubiquitin proteasome system (FTLD-UPS) [36, 95].
Correlations were noted between the clinical FTLD subtypes and underlying proteinopathies, but a strict one-to-one relationship is lacking. An FTLD-FUS proteinopathy is invariantly associated with a clinical diagnosis of bvFTD, either with or without the signs of MND. However, bvFTD is also associated with FTLD-tau and FTLD-TDP (Fig. 1). Although PNFA and SD are both associated with FTLD-tau and FTLD-TDP, PNFA is commonly associated with tau pathology, especially when AOS or orofacial apraxia is present. On the other hand, SD is, in most cases, linked with TDP-43-immunoreactive pathology, although tau pathology is sometimes observed. When SD is associated with FTLD-tau, patients often present with acalculia [122]. In right-sided SD, the underlying neuropathology is mostly a TDP-43 proteinopathy. Tau pathology was also associated with FTD with parkinsonism, PSP syndromes, CBS and AGD. Similarly, TDP-43 and FUS proteinopathies are also commonly found in MND with or without FTLD.

Molecular genetics

Positive family history is observed in 40–50 % of the FTLD patients [85] and at least 10–50 % of the patients are associated with an inheritance pattern compatible with a highly penetrant Mendelian mutation [32, 107]. When considering clinical FTLD subtypes, family history is most prominent in bvFTD (45 %), especially when concomitant symptoms of MND are present (60 %), while SD appeared to be the least hereditary FTLD subtype (<20 %) [56]. Molecular genetic studies have identified five genes that, when mutated, cause FTLD: C9orf72, granulin (GRN), the microtubule associated protein tau gene (MAPT), the gene encoding valosin-containing protein (VCP) and the charged multivesicular body protein 2B (CHMP2B) [30]. Mutations in common ALS genes TARDBP and FUS (see ALS review in this issue), in rare cases, present clinically with FTLD [8, 171], even without the observed signs of MND (e.g. [68]). The relative mutation frequencies of these genes vary substantially among different populations due to founder effects resulting in a regionally high occurrence of one or a limited number of specific mutations. Also, reported mutation frequencies vary significantly between studies, depending on the method of patient ascertainment (e.g. population-based vs. hospital-based) and employed inclusion criteria (e.g. clinical vs. pathological diagnosis, familial vs. non-familial or both). However, in general terms, mutations in C9orf72, GRN and MAPT are the most common and together explain at least 17 % of the familial FTLD (Table 2). In two genetically fully documented FTLD series, summed C9orf72, GRN and MAPT mutation frequencies were 32 [33] and 40 % [55]. Mutations in VCP and CHMP2B are rare, each explaining less than 1 % of the familial FTLD.

As the mutant gene is initiating the biological disease processes underlying the neuropathological changes, a relatively strict correlation between the affected gene and associated neuropathology is observed (Fig. 1). However, due to the lack of a tight correlation between the type of pathology and the clinical manifestation thereof, the
correlation between the disease gene and associated clinical phenotype is limited.

In addition to the highly penetrant Mendelian FTLD genes, few susceptibility genes are reported. From the Mendelian genes, MAPT appears to also harbor a genetic risk to develop tauopathies [6, 64]. The only systematic genome-wide association study in FTLD reported until today identified TMEM106B at chromosome 7p21 as a risk factor for FTLD-TDP [165].

**Autosomal dominant genes**

**MAPT**

The first significant genetic linkage found in FTLD families was with markers at chromosome 17q21 [69, 120, 154]. Linkage was described in 13 families in which a consensus clinical syndrome of autosomal dominant disinhibition, dementia, parkinsonism, and amyotrophy was found, termed FTDP-17 [47]. As tau was implicated in FTLD pathology and the chromosomal location of MAPT coincided with the linkage at chromosome 17, MAPT was the most obvious candidate gene and mutations were identified in FTDP-17 families [69]. Today, 44 different MAPT mutations are reported in 134 FTLD families [30] (Table 2). The mutations are mainly clustered in the five most 3′ exons from 9 to 13, encoding the four microtubule-binding domains of tau. In normal brain, the tau protein occurs as six isoforms of which three contain three microtubule-binding domains (3R tau) and three contain four microtubule-binding domains (4R tau) [41]. A substantial number of mutations were located in the intron 10 splice donor site or intronic splice regulatory elements resulting in aberrant splicing of exon 10. Interestingly, MAPT exon 10 encodes one of the microtubule-binding domains and the mutations affecting the splicing of this exon result in aberrant ratios of 3R and 4R tau [38]. Synonymous and nonsynonymous mutations in exon 10 were shown to locate in exonic splice regulatory elements resulting in similar aberrant splicing effects [39]. In addition, missense mutations are identified that affect the amino acid sequence of the microtubule-binding domains. Mutations affect the binding of tau to tubulin either due to an increased expression of 4R tau relative to 3R tau isoforms, or due to the altered binding properties of mutant tau protein [123]. The mutations thus disturb the subtle equilibrium between cytoskeletal assembly and disassembly affecting neuronal plasticity and axonal transport across the microtubules. In addition, coding MAPT mutations increase the tendency of tau to form neurotoxic aggregates. Mutations in exon 10 lead to 4R tau in both neurons and glia, while mutations outside exon 10 lead to neuronal accumulation of 3R tau and 4R tau [133]. Except for p.P301L and IVS10+16C>T that occur in 32 and 27 families, respectively, MAPT mutations are rare and seen in single families.

FTLD due to MAPT mutations is invariably of the pathological type FTLD-tau, including PiD. In PiD pathology, the cardinal microscopic features are neuronal intracytoplasmatic spheroid tau-containing Pick bodies in the granular neurons of the dentate gyrus and in pyramidal neurons of the hippocampus and affected neocortical regions (Fig. 2a–c). Pick bodies, mainly localized in cortical layers II and III, and to a lesser extent also in deeper layers [41], specifically accumulate insoluble 3R tau [35, 41, 48, 73]. In addition to FTLD-tau, MAPT mutations have also been associated with other tauopathies including PSP, CBS, FTD with parkinsonism and the rarely seen AGD [73, 79]. The typical tau lesions in PSP are globous neurofibrillary tangles (NFT) found in neurons of the subcortical nuclei [35, 41, 73]. In CBS patients, heterogeneous tau-immunoreactive inclusions are also found in cortical neurons and neurons in substantia nigra and locus coeruleus. Other characteristic hallmarks are astrocytic plaques containing hyperphosphorylated tau and oligodendrogial inclusions [35, 41]. The neuropathological hallmark of FTD with parkinsonism is the combination of tau-immunoreactive aggregates in neurons, astrocytes and oligodendroglial cells, throughout cortex, deep gray and subcortical white matter [35, 41]. Often, these lesions are already extensive in early and intermediate stages of the disease. In AGD, on external macroscopic examination, mild diffuse cortical atrophy is seen, with a predilection of the ambient gyrus [35, 44]. The histopathological hallmark is the presence of argyrophilic grains (ArG). These ArG are present throughout the neuropil of cortical and subcortical structures. Lesions are initially present in the amygdala and temporal allocortex, spreading toward temporal neocortex as disease progresses.

FTLD-tau is mainly associated with bvFTD, however, forms of PPA are also reported [105]. Symptoms of MND are rare. On average, FTLD-tau is characterized by the earliest onset age in the FTLD syndromes, although the range of onset ages is large and strongly overlapping with other types of FTLD. A literature survey of 228 FTLD patients carrying a MAPT mutation demonstrated that the average onset age was 48 ± 10 years with a disease duration of 9 ± 5.5 years [27].

**GRN**

In some families linked to chromosome 17q21, extensive mutation analyses could not identify a MAPT mutation. It became apparent that, in FTLD families negative for MAPT mutations, the characteristic pathological inclusions
were of the tau-negative, ubiquitin-positive types suggesting that mutations in another gene at the same genetic locus were causing this FTLD-U type of disease. Extensive mutation analyses of other positional candidate genes identified mutation in the nearby *GRN* gene [7, 28]. To date, 69 different *GRN* mutations have been reported in 231 families [30] (Table 2). *GRN* mutations are distributed across the complete coding region and splice sites of the gene. They are loss-of-function mutations leading to reduced functional protein and resulting in haplo-insufficiency [52]. Most mutations produce null alleles as a result of mRNA decay mediated by a nonsense or frameshift mutation [7, 28, 50], but other mechanisms including gene deletion [53] and defective protein sorting [143] are described as well. *GRN* encodes progranulin, a ubiquitously expressed growth factor precursor consisting of 7.5 granulin peptides [1]. Both full-length progranulin and the granulin peptides are implicated in a wide range of biological processes such as inflammation and wound repair, as well as in pathological conditions including tumorigenesis [62]. Although their roles in the CNS are not well established, in vitro and in vivo studies suggest a neurotrophic function involved in neuronal survival and neurite outgrowth [2, 138, 164, 178].

The effect of *GRN* missense mutations on reduced function and resulting phenotype is not straightforward: some compromise protein stability or cellular sorting, which might result in complete loss of function and lead to haplo-insufficiency, thereby behaving as highly penetrant FTLD mutations. Clear examples of loss-of-function (LOF) missense mutations are those disrupting the signal peptide [104, 143] or affecting the disulfide bonds controlling the characteristic granulin fold [166]. Other missense mutations might only partially compromise function and behave as risk alleles [29]. *GRN* missense mutations have been implicated in AD risk [15, 150] and survival in ALS [184]. A useful measure of the reduced GRN function, discriminating between pathogenic and neutral missense mutations, is the granulin protein level in cerebrospinal fluid [22, 164], plasma [21, 45] and serum [149], although the correlation between protein expression level and associated disease risk is poorly studied.

All *GRN*-associated FTLD patients have a FTLD-TDP proteinopathy [4, 117]. The presence of TDP-43 positive inclusions is invariably associated with a decreased physiologically normal nuclear staining [36, 95]. Recent neuropathological studies elicited four FTLD-TDP subtypes A to D based on the cortical distribution, intracellular location and morphology of the inclusions [99] (Table 1; Fig. 3). Based on the large clinicopathological studies, the most common FTLD-TDP subtype is type A accounting for 41–49 % of the cases, followed by type B with 28–34 % and type C with 17–25 %, while type D is rare [19, 73]. All *GRN* mutations are associated with FTLD-TDP type A (Fig. 3a–c), and in turn mutations in *GRN* explain about 40 % of these cases [133]. In FTLD-TDP type A, many neuronal cytoplasmic inclusions (NCl), short dystrophic neurites (DN) and some lentiform neuronal intranuclear

---

Fig. 2 FTLD-tau pathology in brain sections of a Pick disease patient with bvFTD after immunostaining with AT8 antibody. a Frontal cortex (*F-cx*), b temporal neocortex (*T-cx*), c hippocampus. *Arrowheads* indicate the characteristic Pick bodies representing neuronal intracytoplasmatic spheroid tau inclusions.
inclusions (NII) are observed in layer II of the affected neocortex. NCI in the dentate granular gyrus of the hippocampus are variable in number [99].

Despite the fact that haplo-insufficiency is the common disease mechanism in all patients carrying a GRN mutation, the associated clinical phenotype is variable, including bvFTD and PNFA [88, 125]. Parkinsonian symptoms are often observed, but motor neuron symptoms are rare [23]. Sporadically, clinical diagnoses of related neurodegenerative diseases including AD and parkinsonian disorders have been associated with GRN mutations [14, 21, 22, 88]. A literature survey of 183 patients with GRN-associated FTLD demonstrated that the onset age was on average 61 ± 9 years and 13 years later than in MAPT mutation carriers although as in FTLD-tau, onset ages are highly variable, ranging from 35 to 87 years [29, 30]. A considerable age-dependent penetrance was described with 50–60 % of the mutation carriers being affected by the age of 60 years and 90–95 % by the age of 70 years [50, 125]. Consequently, family history is not always apparent and GRN mutations are found in a significant number of FTLD patients classified as being sporadic [87].

C9orf72

Genetic linkage [12, 54, 89, 93, 102, 162, 163] and association [83, 144, 170] studies in FTLD-TDP, FTLD-ALS and ALS suggested a common genetic defect located at chromosome 9p21 in the complete spectrum of diseases in the FTLD-MND complex [55]. Extensive mutation analyses of positional candidate genes identified an expanded noncoding G₄C₂ hexanucleotide repeat in C9orf72 explaining linkage and association [33, 55, 128]. A literature survey of 183 patients with GRN-associated FTLD demonstrated that the onset age was on average 61 ± 9 years and 13 years later than in MAPT mutation carriers although as in FTLD-tau, onset ages are highly variable, ranging from 35 to 87 years [29, 30]. A considerable age-dependent penetrance was described with 50–60 % of the mutation carriers being affected by the age of 60 years and 90–95 % by the age of 70 years [50, 125]. Consequently, family history is not always apparent and GRN mutations are found in a significant number of FTLD patients classified as being sporadic [87].

Table 1 Major genetic causes, clinical phenotypes and neuropathological characteristics of FTLD-TDP subtypes

| Subtypes of FTLD-TDP | Associated gene mutationsa | Associated clinical phenotype | Neuropathological findings |
|---------------------|---------------------------|------------------------------|-----------------------------|
| Type A              | GRN, C9orf72              | bvFTD (PNFA)                 | Many NCI and DN in superficial cortical layers (layer II) NII in superficial cortical layers GCI |
| Type B              | C9orf72                   | FTD-MND bvFTD               | NCI throughout the entire cortical thickness NII in hypoglossal nucleus and in ventral horn of the spinal cord Pre-inclusions |
| Type C              | SD (bvFTD)                |                              | Long DN in superficial cortical layers Few NCI and NII |
| Type D              | VCP                       | IBMPF D                      | Many NII and DN throughout the entire cortical thickness Few NCI |

bvFTD behavioral variant frontotemporal dementia, PNFA primary nonfluent aphasia, FTD-MND frontotemporal dementia with motor neuron disease, SD semantic dementia, IBMPF D inclusion body myopathy, Paget disease of bone and frontotemporal dementia, NCI neuronal cytoplasmic inclusions, NII neuronal intranuclear inclusions, GCI glial cytoplasmic inclusions, DN dystrophic neurites

a See Table 2 for full gene names
Polyclonal antibodies against both protein Staining of C9orf72 itself has until today remained highly specific for the hippocampus and throughout the neocortex was shown to be to ubiquilin (UBQLN) in the molecular layer of the hippocampus and the granular layer of the cerebellum [13]. The presence of DN and aggregates that were immunoreactive to ubiquilin (UBQLN) in the molecular layer of the hippocampus and throughout the neocortex was shown to be highly specific for the C9orf72 mutation. Further, UBQLN and p62 colocalized in NCI in the dentate gyrus of the hippocampus and the granular layer of the cerebellum [13]. Staining of C9orf72 itself has until today remained inconclusive. Polyclonal antibodies against both protein isoforms showed a punctiform staining of synaptic terminals in the CA4 region of the hippocampus in patients with the C9orf72 mutation, but also in patients with AD and controls [13, 33, 146].

C9orf72 repeat expansions clinically present with a widely variable phenotype including FTLD, ALS or FTLD-ALS [33, 55, 128]. With a mutation frequency of 30 % in FTLD-ALS [55], it is the only known common disease gene in this condition. Independent of concomitant ALS, FTLD is mostly of the behavioral type but patients with PPA have been described [33, 55, 146, 152]. Reported mean onset ages ranged between 55.3 and 58.3 years [33, 55, 146, 152] and are intermediate to onset ages in FTLD associated with MAPT and GRN. Also here, a high variability in onset age was noted, even among patients of the same family [33, 55]. Typical of repeat expansion diseases, genetic anticipation has been suggested with decreasing onset ages in younger generations [5, 24, 43, 156], and a decrease in onset age of 7 years in the younger of two subsequent generations has been suggested for ALS [24]. However, reports correlating sizes of the expanded repeat allele and onset age are lacking.

VCP

VCP mutations were identified by linkage analysis studies in autosomal dominant families with disabling muscle weakness due to inclusion body myopathy (IBM), oesotelytic bone lesions consistent with PDB and FTLD (IBMPFD) [174]. Today, 17 different mutations have been identified in 41 independent families [30]. Incomplete penetrance was noted for all three clinical characteristic features and patients may present with classical FTLD.

VCP encodes a ubiquitously expressed member of a family of ATPases associated with a wide range of cellular functions through interactions with different adaptor proteins [175]. All IBMPFD mutations reside at the interface between the D1 ATPase and the N-domain of the CDC48-like protein [175]. The best supported hypotheses of the disease mechanism of VCP mutations are disturbed ubiquitin–proteasome mediated protein degradation [31], autophagy [74], or both [75]. FTLD patients with a VCP mutation are associated with TDP-43 proteinopathy type D [176] characterized by large numbers of NCI, NII and DN in affected neocortical regions [99] (Fig. 3g–i). Some inclusions also stain for VCP protein p97 [140].

Symptoms of FTLD due to a VCP mutation become apparent in the mid-50s in 25–30 % of the IBMPFD patients [76, 78, 174]. The incomplete penetrance of the three clinical characteristics IBM, PDB and FTLD is independent of the underlying mutation [76, 78, 108, 174]. However, in FTLD, VCP mutations are rare and represent less than 1 % of the familial FTLD (Table 2).
patients [25, 117]. Other missense mutations have been described in patients with FTLD and/or MND; however, their pathogenic nature remains unclear [30].

**TARDBP and FUS**

Mutations in the genes encoding the TDP-43 (TARDBP) and fused-in-sarcoma (FUS) proteins are typically associated with ALS. TARDBP mutations were initially identified [155] as a direct consequence of the identification of TDP-43-derived protein species as the major constituent of the aggregates found in upper and lower motor neurons of ALS patients without SOD1 mutations and in FTLD-U [4, 117]. Whereas 5 % of the familial ALS patients have a TARDBP mutation, mutations are rarely found in FTLD and FTD-MND [8, 10].

TDP-43 is an RNA-binding protein that forms heterogeneous nuclear ribonucleoprotein complexes (hnRNP) which function in RNA processing activities of several cellular functions, including transcription, RNA splicing and microRNA processing [16, 17, 118]. Missense mutations were found in the C-terminal glycine-rich region involved in protein–protein interactions [118]. Similar to TARDBP, FUS is a member of the hnRNP family. Its location at chromosome 16p11.2, made it an excellent candidate gene to explain previously established genetic linkage to the same chromosomal region in multiple ALS families [137, 139] and mutation analyses of patients in these and other families identified FUS mutations [80]. Although FUS represents an ALS gene, a mutational analysis of the FUS gene in 122 patients with FTLD revealed one novel p.Met254Val mutation in a patient with pure bvFTD. The silico analysis of this missense mutation predicted a pathogenic affect; however, the biologic relevance of this mutation remains elusive [157, 171].

Interestingly, an accumulation of FUS protein in inclusion bodies in neuronal cytoplasm and nucleus was associated with three clinicopathological subtypes of FTLD, defined by specific characteristics and location of NCI and NII [92, 97, 98, 114]. The first type is pathologically characterized by severe atrophy of the caudate nucleus and the frontotemporal cortex. Compact, round to oval kidney-shaped NCI and vermiform NII are localized in neocortex, granule cells of the dentate gyrus, striatum and to a lesser extent in globus pallidus, thalamus and periaqueductal gray matter (Fig. 4a–c). The cerebellar cortex is never affected. NCI and NII are not detected upon hematoxylin–eosin staining and were not immunoreactive to intermediate neurofilament on IHC. This type of FUS pathology is associated with a severe clinical syndrome resembling bvFTD and is referred to as atypical FTLD-U (aFTLD-U) [94]. Onset of disease is early, in 30s or 40s, and disease duration is approximately 7 years [85]. aFTLD-U is the most frequent FTLD-FUS subtype, accounting for 7–20 %

### Table 2 Known FTLD genes

| Gene symbol | Chromosomal location | Gene name | Mutation frequency (%)<sup>a</sup> |
|-------------|----------------------|-----------|-------------------------------|
| C9orf72     | 9p21.2               | Chromosome 9 open reading frame 72 | 14–48 |
| GRN         | 17q21.32             | Progranulin | 3–26                        |
| MAPT        | 17q21.32             | Microtubule-associated protein tau | 0–50 |
| CHMP2B      | 3p11.2               | Chromatin modifying protein 2B  | <1   |
| VCP         | 9p13.3               | Valosin-containing protein | <1   |
| Total       |                      |           | >17                          |

Chromosomal localization, gene symbol and name and estimated mutation frequencies in familial FTLD patients

<sup>a</sup> Mutation frequency ranges were extracted from literature: C9orf72 [101], GRN [52], MAPT [123]

frequently reported FTLD subtypes are bvFTD and SD [176]. Interestingly, a single study reported VCP mutations in 1–2 % of the ALS patients in the absence of dementia symptoms [72, 77].

**CHMP2B**

Linkage analyses in a large Danish FTLD family identified a mutation in CHMP2B at chromosome 3p11.2 [147]. CHMP2B encodes a component of the heteromeric ESCRT-III complex with functions in the endosomal–lysosomal and the autophagic protein degradation pathway. The gene is expressed in neurons of all major brain regions. Mutations affect the C-terminal end of the protein due to aberrant splicing.

CHMP2B mutations were associated with enlarged vacuoles in cortical neurons in the frontal, temporal, parietal and occipital cortices, due to impaired endosome–lysosome fusion [160], and impairment of autophagy [25]. Ubiquitin-immunoreactive NCI do not stain for tau, TDP-43 or FUS antibodies [65, 66], consistent with a pathological classification of FTLD-UPS [100].

The general clinical diagnoses in patients of the large Danish family corresponded to bvFTD, with early personality changes being the most common feature [60]. In other patients, progressive aphasia involvement was described, although no diagnosis of PNFA, SD or LPA could be made. The aphasia is characterized by a reduction in spontaneous speech sometimes leading to mutism and preserved reading and repetition, most consistent with a dynamic aphasia [70, 167]. The average onset age is 58 years, ranging between 46 and 65 years [60, 70]. The CHMP2B p.Gln206His mutation was reported in two ALS patients [25, 117]. Other missense mutations have been...
of FTLD-U cases [94, 131, 142, 161]. The second FTLD-FUS type is characterized by an asymmetric atrophy of frontotemporal cortex and neostriatum, which is less severe than in aFTLD-U [85]. NCI and NII stain with FUS antibodies and to a lesser extent with antibodies against type IV interfilaments, alpha-internexin and neurofilaments. Therefore, this FTLD-FUS type is referred to as neuronal intermediate filament inclusion disease (NIFID) [94, 113]. Clinically NIFID patients usually develop a rapidly evolving FTD syndrome, mostly bvFTD, in combination with motor disorders such as parkinsonian or motor neuron symptoms. Patients usually develop the disease between 40 and 60 years of age, but earlier onset has been described and disease duration is on average approximately 3 years [85]. Considerable neuropathological similarities exist between aFTLD-U and NIFID; however, distinctive differences are observed. In NIFID, FUS-immunoreactive NCI are more extensive and widespread and are particularly numerous in CA1 and subiculum, but not in the granular layer of the dentate gyrus. The NCI morphology in NIFID patients is very heterogeneous, varying from small round to oval or tangle-like and annular shapes [73, 98, 100]. While less FUS-immunoreactive inclusions are seen in aFTLD-U, microscopic evaluation of aFTLD-U patients often shows sclerosis of the hippocampus and subcortical structures, for example, caudate nucleus, putamen and substantia nigra [85]. Another difference could be the presence of the NII, which are variably found in the hippocampus, but rare in other brain regions of NIFID patients, and are far more numerous in aFTLD-U patients [98, 100]. In the third FTLD-FUS type, referred to as basophilic inclusion body disease (BIBD), basophilic NCI staining with hematoxylin and eosin are seen in the pontine nuclei and to a lesser extent also in cerebral cortex [73, 98, 100, 106]. The basophilic NCI show FUS immunoreactivity in frontal cortex, basal ganglia and brain stem [98, 100]. BIBD presents with a clinical syndrome of early-onset ALS, occasionally accompanied with bvFTD.

Susceptibility genes and risk loci

Compared with other complex neurodegenerative brain diseases including AD, little is known about susceptibility genes contributing to the risk of developing FTLD. This is mainly due to the fact that the familial component in FTLD is higher, and most research efforts aimed at the identification of Mendelian gene mutations. Also, the clinical and neuropathological heterogeneity of FTLD diseases have hampered large-scale genetic association studies in homogeneous patient series. One exception is the genome-wide association study in FTLD-TDP which has resulted in the identification of TMEM106B at chromosome 7p21 [165]. Nevertheless, other susceptibility genes are to be expected especially in the SD type of FTLD, in which family history is much less pronounced than in bvFTD and PNFA [32]. Consistent with this observation, mutations in the known

Fig. 4 aFTLD-U patient with FUS pathology without any known mutation after immunostaining with FUS antibody. The arrowhead shows the kidney-shaped NCI in affected neostriatum (a) and frontal cortex (b, c, higher magnification)
FTLD genes were not associated with SD apart from a few atypical cases. Interestingly, SD is associated with a distinct type C of TDP-43 pathology suggesting a distinct disease mechanism [73]. FTLD-TDP type C is characterized by the presence of long DN localized in the superficial cortical layers, mainly layer II. NCI and NII are rare or absent compared to the other subtypes. Glial pathology is rare [99]. Together, these observations might suggest that SD is clinically, pathologically and genetically distinct from other types of FTLD and might predominantly be caused by the interaction of multiple yet unknown susceptibility genes.

**TMEM106B** was the only gene located in a single linkage disequilibrium block at 7p21 in which multiple single nucleotide polymorphisms (SNPs) were significantly associated in a series of 515 FTLD-TDP patients, a finding that was replicated in a second series of 89 FTLD-TDP patients [165]. In subsequent studies, association could be confirmed in one patient series [169], but not in another series [135]. It was found that **TMEM106B** may also contribute to the risk of developing FTLD in carriers of **GRN** mutations [165] possibly by modulating the levels of **GRN** secretion [26], however, other studies were not consistent with these findings [84, 169]. Interestingly, **TMEM106B** may also be associated with cognitive impairment in ALS [173].

**TMEM106B** is a type 2 integral membrane protein with unknown function, localizing to late endosomes and lysosomes [84]. The chromosome 7p21 risk haplotype was reported to act through altered **TMEM106B** gene expression in brain [165], although this was not confirmed in another study [169]. Interestingly, increased levels of **TMEM106B** were also associated with the inhibition of vacuolar H+-ATPases, a finding which may provide an unexpected biochemical link to **GRN**, since this protein is also strongly increased by the inhibition of vacuolar H+-ATPases [84].

Apart from the systematic genome-wide association study in FTLD-TDP [165], candidate gene association studies have reported genetic association of FTLD with other genes. In a series of pathologically confirmed FTLD-U patients without **GRN** mutations, a common genetic variant located in the 3′-untranslated region (UTR) of **GRN** in a binding site for miR-659 was identified as a major susceptibility factor for FTLD-U [126]. A significant reduction of **GRN** protein was observed in homozygous T-allele carriers in vivo, suggesting a similar mode of action as heterozygous loss-of-function mutations in **GRN** [126]. Another variant in the first intron of **GRN**, potentially affecting its expression, was also reported to be associated with FTLD in another patient series [49]. Nevertheless, other studies could not confirm the genetic risk for FTLD associated with variants in **GRN** [134, 152].

Besides harboring Mendelian FTLD mutations, **MAPT** was associated with risk of PSP [6, 64, 67], CBS [37, 67] and PD [40, 159], but inconsistent results were found in FTLD [9, 51, 86]. **MAPT** is represented in the human population as two genetically distinct haplotypes H1 and H2 due to its genomic location inside an inversion polymorphism [27]. The H1 haplotype is consistently overrepresented in 4R tau disorders, PSP and CBD [6, 67]. In young PSP patients, the risk was in part attributed to an SNP located in the large first intron of **MAPT**, which potentially modulated tau expression by modifying an LBP-1c/LSF/CP2 binding site. This transcription factor was shown to regulate the expression of genes in other neurodegenerative disorders [124]. A two-staged genome-wide association study in 2,165 PSP patients confirmed and extended these findings, and further implicated **STX6, EIF2AK3**, and **MOBP** in PSP [64]. Together, these genes suggested roles of vesicle-membrane fusion at the Golgi–endosomal interface, the endoplasmic reticulum unfolded protein response, and a myelin structure in PSP. The role of these genes in other tauopathies remains to be investigated.

**Summary**

FTLD is a clinically, neuropathologically and genetically heterogeneous group of disorders with plenty of overlaps between the neurodegenerative mechanism and the clinical expression thereof. As many clinical syndromes belonging to FTLD tend to overlap especially in advanced disease stages, e.g. SD and bvFTD in the TDP-43 proteinopathies, aFTLD-U and NIFID in the FUS proteinopathies, identifying the symptomatology of the patient at an early stage of the disease course is crucial. In that respect, concerted evaluation of clinical and pathological parameters is helpful to obtain a precise diagnosis. The general clinical presentation of FTLD concurs with macroscopic characteristics of brain atrophy including localization, symmetry and degree of atrophy. The underlying neuropathological abnormalities, i.e. the proteinopathies are closely linked with the disease mechanism and are important diagnostic markers. Detailed information on the underlying neuropathology thus provides useful insights for early diagnosis, disease course prognosis and patient counseling and treatment that could not be obtained by clinical evaluation alone. Imaging, biological and genetic biomarkers are valuable parameters to assess the underlying pathological characteristics of the disease. Further research is needed to elicit additional biomarkers to extend the ability to characterize neuropathological causes of disease and to further specify clinicopathological correlations.

Despite immense progress in defining neuropathological abnormalities in FTLD diseases, not all FTLD...
proteinopathies are fully characterized yet. In the small group of FTLD-UPS patients, the protein accumulating in pathological aggregates remains to be identified. Similarly, not all mutations underlying the proteinopathies have been identified. Especially in the TDP-43 proteinopathies, several yet unknown Mendelian and susceptibility genes are expected to play a role. Specifically for FTLD-TDP type C, no gene has yet been identified. This type of proteinopathy is associated with clinical SD, in which family history was reported to be the least prominent and future, genome-wide, association studies may provide further insights in the genetics of this disease.

Acknowledgments The authors are grateful to the participants to this study for their kind cooperation. We acknowledge the contribution of the lab technician Karen Sterck and photographer Inge Bats. We further thank the medical doctors in collaboration Dr. Adrian Ivanou, Dr. Alex Michotte, Dr. Jan Versijpt, Dr. Oliervey, Dr. Chris Willems, Dr. Boudewijn Michielsen, Dr.Alexandra Keersmaekers, Dr. Dirk Ververken, Dr. Jen Maes, Dr. Philippe Maere, Dr. Marc Bruyland who recruited patients to this study and Keersmaekers, Dr. Dirk Ververken, Dr. Jen Maes, Dr. Philippe Maere, Dr. Marc Bruyland who recruited patients to this study and provided clinical data. We further thank the personnel of the Genetic Service Facility of VIB (http://www.vibgeneticservicefacility.be), the Antwerp Biobank of the Institute Born-Bunge and the neurological departments of the participating hospitals. None of the funding agencies listed below had a role in writing of the manuscript or the decision to submit for publication. All funding sources are listed and were from public or private research organizations. The research was in part funded by the European initiative on Centers of Excellence in Neurodegeneration (CoEN), the Special Research Fund of the University of Antwerp, the Research Foundation—Flanders (FWO) and the Agency for Innovation by Science and Technology—Flanders (IWT), the Methusalem excellence grant of the Flemish Government, the Interuniversity Attraction Poles program (IUAP) P7/16 of the Belgian Science Policy Office, the Stichting Alzheimer Onderzoek (SAO-FRMA) and the Queen Elisabeth Medical Foundation (QEMF). The FWO provided a clinical investigator mandate to A.S. and the IWT a PhD fellowship to T.V.L.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW (2007) Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflam 4:7
2. Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuerzter CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, McGowan E, Dickson DW, Lewis J (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol 177(1):311–324
3. Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodl I, Rogelj B, Al-Chalabi A, Hortobagyi T, Shaw CE (2011) p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72 linked FTLD and MND/ALS. Acta Neuropathol 122(6):691–702
4. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351(3):602–611
5. Arighi A, Fumagalli GG, Jacini F, Fenoglio C, Ghezzi L, Pietroboni AM, De Riz M, Serpente M, Ridolfi E, Bonsi R, Bresolin N, Scarpini E, Galimberti D (2012) Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis (Epub ahead of print)
6. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8(4):711–715
7. Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442(7105):916–919
8. Benajiba L, Le Ber I, Camuzat A, Lacoeste M, Thomas-Antieron C, Courratier P, Legaistic S, Salachas F, Hammequin D, Decousus M, Lacambles L, Guedj E, Gollier V, Camu W, Dubois B, Campion D, Meininger V, Brice A, French Clinical and Genetic Research Network on Frontotemporal Lobar Degeneration/ Frontotemporal Lobar Degeneration with Motor Neuron Disease (2009) TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 65(4):470–473
9. Borroni B, Yanocopoulou D, Tsutsumi M, Padovani A, Sawai JK, Hodges JR, Spillantini MG (2005) Association between tau H2 haplotype and age at onset in frontotemporal dementia. Arch Neurol 62(9):1419–1422
10. Borroni B, Bonvicini C, Alberici A, Buratti E, Agosti C, Archetti S, Papetti A, Stuani C, Di Luca M, Gennarelli M, Padovani A (2009) Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat 30(11):E974–E983
11. Borroni B, Archetti S, Del Bo R, Papetti A, Buratti E, Bonvicini C, Agosti C, Cossecud M, Turla M, Di Lorenzo D, Pietro Comi G, Gennarelli M, Padovani A (2010) TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res 13(5):509–517
12. Boxer AL, Mackenzie IR, Boeve BF et al (2010) Clinical, neuroimaging and neuropathological features of a novel chromosome 9p-linked FTLD-ALS family. J Neurol Neurosurg Psychiatry 82:196–203
13. Brettschneider J, Van Deelen VM, Robinson JL, Kwong L, Lee EB, Ali YO, Safren N, Monteiro MJ, Toledo JB, Elman L, McCluskey L, Irwin DJ, Grossman M, Molina-Porcel L, Lee VM, Trojanowski JQ (2012) Pattern of ubiquitin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol 123(6):825–839
14. Bravreaux N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, Bogaerts V, De Pooter T, Serneels S, Van den Broeck M, Cuijt I, Matheijssens M, Peeters K, Scirot R, Martin JJ, Cras P, Santens P, Vandenbergh R, De Deyn PP, Cruts M, Van Broeckhoven C, Sleegers K (2007) Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 64(10):1436–1446
24. Chio A, Borghero G, Restagno G, Mora G, Drepper C, Traynor JJ, Cruts M, De Deyn PP, Van Broeckhoven C (2008) Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease. Neurology 71(9):656–664

25. Cruts M, Rademakers R, Gijselinck I, van der Zee J, Dermaut B, de Poorter T, de Rijk P, Del-Favero J, van Broeckhoven C (2005) Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum Mol Genet 14(13):1753–1762

26. Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S, Mayo K, Norton JB, Morris JC, Goate A (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol 68(5):581–586

27. Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenberghge R, Dermaut B, Martin JJ, van Duijn C, Peeters K, Sciot R, Santens P, De Poorter T, Mattheijssens M, Van den Broeck M, Cuiti J, Vennekens K, De Deyn PP, Kumar-Singh S, Van Broeckhoven C (2006) Null mutation in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442(7105):920–924

28. Cruts M, Van Broeckhoven C (2008) Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet 24(4):186–194

29. Cruts M, Theuns J, Van Broeckhoven C (2012) Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. doi:10.1002/humu.22117

30. Dai RM, Li CC (2001) Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 3(8):740–744

31. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM, Xuereb JH (2005) The pathological basis of semantic dementia. Brain 128(Pt 9):1984–1995

32. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat expansion in non-coding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neurology 72(2):245–256

33. De Letter M, Van Borsel J, Dewulf J, Santens P (2011) Dysfluencies in pure akinesia with gait freezing : two case reports. J Neurolinguist 24:352–356

34. Dickson D, Weller R (2011) Neurodegeneration: the molecular pathology of dementia and movement disorders, part 3. Wiley-Blackwell, West Sussex, pp 105–190

35. Dickson D, Weller R (2011) Neurodegeneration: the molecular pathology of dementia and movement disorders, part 7. Wiley-Blackwell, West Sussex, pp 389–436

36. Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, Frasson E, Marchese R, Montagna P, Munoz DG, Pramstaller PP, Zanussi G, Ajmar F, Mandich P (2000) CORTICObasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 47(3):374–377
38. D’Souza I, Schellenberg GD (2000) Determinants of 4-repeat tau expression. Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. J Biol Chem 275(23):17700–17709

39. D’Souza I, Schellenberg GD (2002) Tau Exon 10 expression involves a bipartite intron 10 regulatory sequence and weak 5’ and 3’ splice sites. J Biol Chem 277(29):26587–26599

40. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Züchner S, Konidari I, Wang G, Singer C, Nahaf F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74(2):97–109

41. Ellison D, Love S, Chimelli L, Harding BN, Lowe J, Vinters HV (2004) A reference text of CNS pathology. In: Chapter 9: neurodegenerative diseases Elsevier Limited. ISBN: 0 7234 3329 2

42. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng J, Shi Y, Siddique N, Arrat H, Donkervoort S, Ajroud-Driss S, Sufit RL, Heller SL, Deng RX, Siddique T (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68(11):1440–1446

43. Ferrari R, Mok K, Moreno JH, Cosentino S, Goldman J, Pietrini P, Mayeux R, Tierney MC, Kapogiannis D, Jicha GA, Murrell TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kominos VE (2006) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 65(6):571–581

44. Forman MS, Mackenzie IR, Cairns NJ, Swanson K, Kuntz K, Melquist S, Petersen R, Josephs K, Pickering-Brown SM, Graff-Radford N, Uitti R, Dickson D, Jhaveri BS, Karlawish JH, Pestronk A, Smith Arch Neurol 68(11):1817–1819

45. Foster NL, Wilhelmsen K, Sima AA, D’Amato CJ, Groth J, Janssens K, Cattaneo S, Shi Y, Siddique N, Arrat H, Donkervoort S, Ajroud-Driss S, Sufit RL, Heller SL, Deng RX, Siddique T (2011) SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68(11):1440–1446

46. Gijselinck I, Engelborghs S, Goossens D, Peeters K, Matteijssens M, Corserit E, Del-Faverio J, De Dehn PP, Van Broeckhoven C, Cruts M (2008) Progranulin locus deletion in frontotemporal dementia. Hum Mutat 29(1):53–58

47. Gijselinck I, van der Zee J, Engelborghs S, Goossens D, Peeters K, Matteijssens M, Corserit E, Del-Faverio J, De Dehn PP, Van Broeckhoven C, Cruts M (2008) Progranulin locus deletion in frontotemporal dementia. Hum Mutat 29(1):53–58

48. Gijselinck I, Van Langenhove T, van der Zee J, Sleekers K, Huljings S, Kleinberger G, Janssens J, Bettens K, Van Cauwenberghes C, Pereson S, Engelborghs S, Sieben A, De Jonghe P, Vandenbergher R, Santens P, De Bleecker J, Maes G, Bäumer V, Dillen L, Joris G, Cuijt I, Corserit E, Elincck E, Van, Dongen J, Vermeulen S, Van den Broeck M, Vaerenberg C, Matteijssens M, Peeters K, Robberecht W, Cras P, Martin JJ, De Dehn PP, Cruts M, Van Broeckhoven C (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11(1):54–65

49. Goldstein JS, Farmer JM, Wood EM, Johnson JK, Boxer A, Neuhaus J, Lomen-Hoerth C, Wilkinson KC, Lee VM, Grossman M, Miller BL (2005) Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65(11):1817–1819

50. Goldman JS, Adamson J, Karydas A, Miller BL, Hutton M (2007) New genes, new dilemmas: FTLD genetics and its implications for families. Am J Alzheimers Dis Other Demen 22(6):507–515

51. Goode A, Layfield R (2010) Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol 63(3):199–203

52. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, Ogar JM, Roehr JD, Black S, Boeve BF, Manes F, Dronkers NF, Vandenbergher R, Rascovsky K, Patterson K, Millcr BL, Knopman DS, Hodges JR, Mesulam MM, Grossman M (2011) Classification of primary progressive aphasia and its variants. Neurology 76:1006–1014

53. Gudelis J, Gormley PJ, Wijmenga C, Collinge J, Sorensen SA (2002) Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology 59(10):1585–1594

54. Hassan A, Whitwell JL, Josephs KA (2011) The corticobasal syndrome-Alzheimer’s disease conundrum. Expert Rev Neurother 11(11):1569–1578

55. He Z, Bateman A (2003) Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 81(10):600–612

56. Hodges JR, Davies R, Xuereb J, Kriel J, Halliday G (2003) Survival in frontotemporal dementia. Neurology 61(3):349–354

57. Höglund GU, Melhem NM, Dickson DW, Siepmann PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Springer
Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD (2011) Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 43(7):699–705

65. Holm IE, Englund E, Mackenzie IR, Johansson P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol 66(10):884–891

66. Holm IE, Isaacs AM, Mackenzie IR (2009) Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHM2P gene. Acta Neuropathol 118(5):719–720

67. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56(12):1702–1706

68. Huey ED, Ferrari R, Moreno JH, Jensen C, Morris PM, Potocnik F, Kalaria RN, Tierney M, Wassermann EM, Hardy J, Graftman J, Momeni P (2011) FUS and TDP43 genetic variability in FTD and CBS. Neurobiol Aging (Epub ahead of print)

69. Hutton M, Lendon CL, Mackenzie IR, Johansson P, Isaacs AM (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHM2P gene. Acta Neuropathol 118(5):719–720

70. Isaacs AM, Johansson P, Holm I, Nielsen JE, FReJA consortium (2011) Frontotemporal dementia caused by CHM2P2 mutations. Curr Alzheimer Res 8(3):246–251

71. Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman RK, Dickson D, Capell A, Haass C (2012) Membrane orientation and subcellular localization of transmembrane protein 106B fused in sarcoma proteinopathies. Brain 134(Pt 9):2548–2564

72. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin V, Lynch T, Heutink P (1998) Association of missense and mon tau haplotype. Neurology 56(12):1702–1706

73. Josephs K, Hodges J, Snowdon J, Mackenzie I, Neumann M, Mann D, Dickson D (2011) Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:137–153

74. Ju JS, Weihl CC (2010) Inclusion body myopathy, Paget’s disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum Mol Genet 19(R1):R38–R45

75. Ju JS, Weihl CC (2010) p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Autophagy 6(2):283–285

76. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, Neilan EG, Kartashov A, Forman MS, Tucker S, Kimonis K, Mumm S, Whyte MP, Smith CD, Watts GD (2008) Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 146A(6):745–757

77. Koppermann M, van Blitterswijk MM, Vlam L, Rowicka PA, van Vught PW, Groen EJ, Spliet WG, Engelen-Lee J, Schelhaas HJ, de Visser M, van der Kooi AJ, van der Pol WL, Pasterkamp RJ, Veldink JH, van den Berg LH (2011) VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging (Epub ahead of print)

78. Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, Shanks CA, Gregg G, Al-Lozzi MT, Miller T, Rakowicz W, Lopate G, Florence J, Giossor G, Simmons Z, Morris JC, Whyte MP, Pestrkon A, Kimonis VE (2001) Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metab 74(4):458–475

79. Kovacs GG, Pittman A, Revesz T, Luk C, Lees A, Kiss E, Tariska P, Laszlo L, Molnar K, Molnar MJ, Tolnay M, de Silva R (2008) MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neuropathol 116(1):103–118

80. Klawitkowski TJ Jr, Bosca DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrest J, Kasarskis EJ, Munsat T, Valdmansis P, Rouleau GA, Hoelzer BA, Cortelli P, de Jong PJ, Yoshinaga Y, Haines JL, Gilchrist-VAKE MA, Yan J, Ticozzi N, Siddique T, McKenna-Yasek D, Sapp PC, Horvitz HR, Landers JE, Brown RH Jr (2009) Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis. Science 323(5918):1205–1208

81. Kumar-Singh S (2011) Progranulin and TDP-43: mechanistic links and future directions. J Mol Neurosci 45(3):561–573

82. Kwong LK, Uryu K, Trojanowski JQ, Lee VM (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16(1):41–51

83. Laaksovirta H, Peuralinna T, Schymick JC et al (2010) Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol 9:978–985

84. Lang CM, Fellerner K, Schwenk BM, Kuhn PH, Kremmer E, Edlbauer D, Capell A, Haass C (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J Biol Chem (Epub ahead of print)

85. Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Morris HR, Bristal RH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergard K, Schroder HD, Bojesen-Mellor M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T (2011) A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134(Pt 9):2548–2564

86. Laws SM, Friedrich P, Diehl-Schmid J, Muller J, Ibach B, Bajun J, Eisele T, Förl H, Kurz A, Riemenschneider M (2008) Genetic analysis of MAPT haplotype diversity in frontotemporal dementia. Neurobiol Aging 29(8):1276–1278

87. Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, Puel A, De Poeter T, Camuzat A, Van den Broeck M, Dubois B, Sellal F, Lacomblez L, Vercelletto M, Thomas-Antérion C, Michel BF, Golletier V, Ducie M, Salachas F, Duyckaerts C, Cruts M, Verpillat P, Van Broeckhoven C, Price A, French Research Network on FTD/FTD-MND (2007) Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 28(9):846–855

88. Le Ber I, Camuzat A, Hannequin D, Pasquier F, Guedj E, Rovelet-Lecrux A, Hahn-Barma V, van der Zee J, Clot F, Bakchine S, Puel M, Ghanim M, Lacomblez L, Mikol J, Deramecourt V, Lejeune P, de la Sayette V, Belliard S, Vercelletto M, Meyrignac C, Van Broeckhoven C, Lambert JC, Verpillat P, Campion D, Habert MO, Dubois B, Brice A, French
research network on FTD/FTD-MND (2008) Phenotype variability in progranulin mutation carriers: a clinical, neuropathological, imaging and genetic study. Brain 131(Pt 3):732–746

89. Le Ber I, Camuzat A, Berger E et al (2009) Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 72(The French Research Network on FTD/FTD-MND):1669–1676

90. Lipton A, White CL III, Bigio EH (2004) Frontotemporal lobar degeneration with motor neuron disease-type inclusions predominates in 76 cases of frontotemporal degenera. Acta Neuropathol 108:379–385

91. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B (2003) Are amytrophic lateral sclerosis patients cognitively normal? Neurology 60(7):1094–1097

92. Love S, Spillantini MG (2011) Unpicking frontotemporal lobar degeneration. Brain 134:2453–2455

93. Luty AA, Kwok JB, Thompson EM et al (2008) Pedigree with tau and TDP-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurosci 8:32

94. Mackenzie IR, Foti D, Woulfe J, Hurwitz TA (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131:1282–1293

95. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117(1):15–18

96. Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, Kovacs GG, Ghetti B, Halliday G, Holm IE, Ince PG, Kamphorst W, Revesz T, Rozemuller AJ, Kumar-Singh S, Akiyama H, Baborie A, Spina S, Dickson DW, Trojanowski JQ, Mann DM (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119(1):1–4

97. Mackenzie IR, Rademakers R, Neumann M (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9(10):995–1007

98. Mackenzie I, Munoz DG, Kusaka H, Yokota O, Ishihara K, Roeb R, Kretzschmar HA, Cairns NJ, Neumann M (2011) Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 121:207–213

99. Mackenzie I, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DMA, Lee VMY (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:111–113

100. Mackenzie IR, Neumann M, Cairns NJ, Munoz DG, Isacs AM (2011) Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43. J Mol Neurosci 45(3):402–408

101. Majounie E, Renton AE, Berger E et al (2009) Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 72(The French Research Network on FTD/FTD-MND):1669–1676

102. Merola M, Al-Chalabi A, Andersen PM et al (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66:839–844

103. Morris HR, Khan MN, Janssen JC, Brown JM, Perez-Tur J, Baker M, Ozansoy M, Hardy J, Hutton M, Wood NW, Lees AJ, Revesz T, Lantos P, Rossor MN (2001) The genetic and pathological classification of familial frontotemporal dementia. Arch Neurol 58(11):1813–1816

104. Mukherjee O, Pastor P, Cairns NJ, Chakraverty S, Kauwe JS, Shears S, Behrens MI, Budde J, Hinrichs AL, Norton J, Levitch D, Taylor-Reinwald L, Gitcho M, Tu PH, Tenenholz Grinberg L, Listic RM, Armendariz J, Morris JC, Goate AM (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol 60(3):314–322

105. Munoz DG, Ros R, Fatas M, Bermejo F, de Yebenes JG (2007) Progressive nonfluent aphasia associated with a new mutation V363I in tau gene. Am J Alzheimers Dis Other Demen 22(4):294–299

106. Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, Kuroda S, Mackenzie IR (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118(5):617–627

107. Murray ME, Dejesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, Wszolek ZK, Ferman TJ, Josephs KA, Boylan KB, Rademakers R, Dickson DW (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 122(6):673–690

108. Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, Nguyen C, Mukherjee J, Caiozzo V, Martin B, Watts GD, Vesa J, Smith C, Kimonis VE (2011) The multiple faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget’s disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci 45(3):522–531

109. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6):1566–1574

110. Neary D, Snowden J, Mann D (2005) Frontotemporal dementia. Lancet Neurol 4(11):771–780

111. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masiah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM (2006) Ubiquitinopathic TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130–133

112. Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM (2007) TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch Neurol 64(10):1388–1394

113. Neumann M, Roeb R, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118(5):605–616

114. Neumann M, Rademakers R, Roeb R, Baker M, Kretzschmar HA, Mackenzie IR (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132(Pt 11):2922–2931
115. Nunnemann S, Last D, Schuster T, Förstl H, Kurz A, Diehl-Schmid J (2011) Survival in a german population with fronto-temporal lobar degeneration. Neuropathology 31(3-4): 160–165

116. Pamphlett R, Cheong PL, Trent RJ, Yu B (2012) Transmission of C9orf72 hexanucleotide repeat expansions in sporadic amyotrophic lateral sclerosis: an Australian trio study. Neurobiol Aging 33(7):1132–1142

117. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Anderson PM, Morrison KE, Pall HS, Hardiman O, Collinge J, Shaw PJ, Fisher EM; MRC Proteomics in ALS Study; FReJA Consortium (2006) ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 67(6):1074–1077

118. Petritis GS, Lee VM, Trojanowski JQ (2009) Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 18(R2):R156–R162

119. Phukan J, Pender NP, Hardiman O (2007) Cognitive impairment in sporadic amyotrophic lateral sclerosis. Lancet Neurol 6(11):994–1003

120. Pookraj T, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadas A, Wiederhold WC, Raskind M, Schellenberg GD (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43(6):815–825

121. Rabinovici GD, Jagust WJ, Frust AJ, Ojar JM, Racine CA, Mormino EC, O’Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML (2008) Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64(4):388–401

122. Rabinovici GD, Millson BJ (2010) Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24(5):375–398

123. Rademakers R, Cruts M, van Broeckhoven C (2004) The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24(4):277–295

124. Rademakers R, Melquist S, Cruts M, van Broeckhoven C, Theuns J, Del-Favero J, Dickson DW, Graff-Radford NR, Dickson DW (2008) Common variation in PGRN 3’UTR rs5848 in frontotemporal lobar degeneration: an association study replication confirms a risk locus shared with Alzheimer disease. Neurology 65(4):586–590

125. Roberson ED, Hesse JH, Rose KD, Slama H, Johnson JK, Yaffe K, Forman MS, Miller CA, Trojanowski JQ, Kramer BL (2005) Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 65(5):719–725

126. Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008) TDP-43-negative FTLD-U is a significant new clinicopathological subtype of FTLD. Acta Neuropathol 116:147–157

127. Rosser JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman DM, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of fronto-temporal lobar degeneration. Neurology 73(18):1451–1456

128. Ruddy DM, Parton MJ, Al-Chalabi A, Lewis CM, Nock BM, Smith BN, Leigh PN, Powell JF, Siddique T, Meyjes EP, Baas F, de Jong V, Shaw CE (2003) Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 9p21. Neurobiol Aging 24(21):3281–3292

129. Ruddy DM, Parton MJ, Al-Chalabi A, Lewis CM, Nock BM, Smith BN, Leigh PN, Powell JF, Siddique T, Meyjes EP, Baas F, de Jong V, Shaw CE (2003) Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 9p21. Neurobiol Aging 24(21):3281–3292

130. Rüdiger R, Dutoit C, Reuter M, Gherardi E, sexReddy M, de Deyn PP, Dickson DW, Graff-Radford NR, Hutton ML (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neurology 72(2):257–268

131. Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M (2008) TDP-43-negative FTLD-U is a significant new clinicopathological subtype of FTLD. Acta Neuropathol 116:147–157

132. Roehr JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman DM, Beck J, Isaacs AM, Authier A, Ferrari R, Fox NC, Mackenzie IR, Warren JD, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of fronto-temporal lobar degeneration. Neurology 73(18):1451–1456

133. Rödiger R, Guerreiro R, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of fronto-temporal lobar degeneration. Neurology 73(18):1451–1456

134. Rödiger R, Guerreiro R, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of fronto-temporal lobar degeneration. Neurology 73(18):1451–1456

135. Rödiger R, Guerreiro R, de Silva R, Holton J, Revesz T, Hardy J, Mead S, Rossor MN (2009) The heritability and genetics of fronto-temporal lobar degeneration. Neurology 73(18):1451–1456

136. Rosso SM, Kamphorst W, de Graaf B, Willemsen R, Ravid R, Niegermeier MF, Spillantini MG, Heutink P, van Swieten JC (2001) Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. Brain 124(Pt 10): 1948–1957

137. Ruddy DM, Parton MJ, Al-Chalabi A, Lewis CM, Nock BM, Smith BN, Leigh PN, Powell JF, Siddique T, Meyjes EP, Baas F, de Jong V, Shaw CE (2003) Two families with familial amyotrophic lateral sclerosis are linked to a novel locus on chromosome 16q. Am J Hum Genet 73(2):390–396
138. Ryan CL, Baranowski DC, Chitramathu BP, Malik S, Li Z, Cao M, Minotti S, Durham HD, Kay DG, Shaw CA, Bennett HP, Bateman A (2009) Progranulin is expressed within motor neurons and promotes neuronal cell survival. BMC Neurosci 27(10):130

139. Sapp PC, Hosler BA, McKenna-Yasek D, Chin W, Gann A, Genise H, Gorenstein J, Huang M, Sailer W, Scheffler M, Valesky M, Haines JL, Pericak-Vance M, Siddiqui T, Vorritz HR, Brown RH Jr (2003) Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am J Hum Genet 73(2):397–403

140. Schröder R, Watts GD, Mehta SG, Evert BO, Broich P, Fliessbach K, Pauls K, Hans VH, Kimonis V, Thal DR (2005) Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol 57(3):457–461

141. Seelaar H, Schelhaas HJ, Azmani A, Küsters B, Rosso S, Majoour-Kraakauer D, de Rijk MC, Rizzu P, ten Brummelhuis M, van Doorn PA, Kamphorst W, Willemsen R, van Swieten JC (2007) TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without progranulin mutations. Brain 130(Pt 5):1375–1385

142. Seelaar H, Klijnsmra KY, de Koning I et al (2010) Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration. J Neurol 257:747–753

143. Shankaran SS, Capell A, Hruscha AT, Fellerer K, Neumann M, Schmidt B, Haass C (2008) Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J Biol Chem 283(3):1744–1753

144. Shatunov A, Mok K, Newhouse S et al (2010) Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol 9:896–904

145. Simón-Sánchez J, Seelaar H, Bochdanovits Z, Deeg DJ, van Swieten JC, Heutink P (2009) Variation at GRN 3′-UTR rs5848 is not associated with a risk of frontotemporal lobar degeneration in Dutch population. PLoS ONE 4(10):e7494

146. Simón-Sánchez J, Dopper EG, Cohn-Hokke PE, Hukema RK, Nicolau L, Seelaar H, de Graaf JR, de Koning I, van Schoor NM, Deeg DJ, Smits M, Raaphorst J, van den Berg LH, Schelhaas HJ, De Die-Smulders CE, Majoour-Kraakauer D, Rozemuller AJ, Willemse R, Pijnenburg YA, Heutink P, van Swieten JC (2012) The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain 135(Pt 3):723–735

147. Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Tufts GA, Brandner S, Brun A, Rossor MN, Gade A, Johansen A, Sorensen SA, Gydesen S, Fisher EM, Collinge J (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37(8):806–808

148. Sleevers K, Brouwers N, Maurer-Stroh S, van Es MA, Van Damme P, van Vught PW, van der Zee J, Serneels S, De Poeter T, Van den Broeck M, Cruts M, Schymkowitz J, de Jonghe P, Roussea F, van den Berg LH, Robberecht W, Van Broeckhoven C (2008) Progranulin genetic variability contributes to amyotrophic lateral sclerosis. Neurology 71(4):253–259

149. Sleevers K, Brouwers N, Van Damme P, Engelborghs S, Gijselinck I, van der Zee J, Peeters K, Mattheijssens M, Cruts M, Vandenbergh R, De Deyn PP, Robberecht W, Van Broeckhoven C (2009) Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 65(5):603–609

150. Sleevers K, Brouwers N, Van Broeckhoven C (2010) Role of progranulin as a biomarker for Alzheimer’s disease. Biomark Med 4(1):37–50

151. Snowden JS, Thompson JC, Stopford CL, Richardson AM, Gerhard A, Neary D, Mann DM (2011) The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 134(Pt 9):2478–2492

152. Snowden JS, Rollinson S, Thompson JC, Harris JM, Stopford CL, Richardson AM, Jones M, Gerhard A, Davidson YS, Robinson A, Gibbons L, Hu Q, DuPlessis D, Neary D, Mann DM, Pickering-Brown SM (2012) Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135(Pt 3):693–708

153. Spillantini MG, Bird TD, Ghetti B (1998) Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol 8(2):387–402

154. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B (1998) Mutation in the tau gene in familial multiple system atrophy with presenile dementia. Proc Natl Acad Sci USA 95:7737–7741

155. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durrall JC, Williams KL, Buratti E, Baralle F, de Bellerocche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319(5870):1668–1672

156. Stewart H, Rutherford NJ, Briemberg H, Krieger C, Cashman N, Fabros M, Baker M, Fok A, DeJesus-Hernandez M, Eisen A, Rademakers R, Mackenzie IR (2012) Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol 123(3):409–417

157. Ticozzi N, Silani V, LeClerc AL, Keagle P, Gellera C, Ratti A, Taroni F, Kwiatkowski TJ Jr, McKenna-Yasek DM, Sapp PC, Brown RH Jr, Landers JE (2009) Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology 73(15):1180–1185

158. Troakes C, Maekawa S, Wijesekera L, Rogelj B, Siklós L, Bell C, Smith B, Newhouse S, Vance C, Johnson L, Hortobágyi T, Shatunov A, Mok K, Newhouse S, Vanc C, Johnson L, Hortobágyi T, Shatunov A, Al-Chalabi A, Leigh N, Shaw CE, King A, Al-Sarraj S (2011) An NMDALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neurology. doi: 10.1111/j.1440-1799.2011.0286.x

159. UK Parkinson’s Disease Consortium; Wellcome Trust Case Control Consortium 2, Spencer CC, Plagol V, Strange A, Gardiner M, Puisan-Ruiz C, Band G, Barker RA, Bellenguez C, Patilania K, Blackburn JM, Bramon E, Brown MA, Brown MA, Burn D, Cashas JP, Chinnery, PCR, Clarke CE, Corvin A, Credock N, Deloukas E, Edkins S, Evans J, Freeman C, Gray E, Hardy J, Hudson G, Hunt S, Jarowicz J, Langford C, Lees AJ, Markus HS, Mathew CG, McCarthy MI, Morrison KE, Morris HR, Donnelly P, Sawcer SJ, Saito Y, Smith A, Durrall JC, Williams NW, Morris HR, Donnelly P, Wood NW (2011) Dissection of the genetics of Parkinson’s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 20(2):345–353

160. Urwin H, Authier A, Nielsen JE, Metcalf D, Powell C, Froud K, Malcolm DS, Holm I, Johansen P, Brown J, Fisher EM, van der Zee J, Bruylant M, FReJA Consortium, VanBroeckhoven C, Collinge J, Brandner S, Futter C, Issacs A (2010) Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum Mol Genet 19(11):2228–2238

161. Urwin H, Josephs KA, Rohrer JD, Mackenzie IR, Neumann M, Authier A, Seelaar H, Van Swieten JC, Brown JM, Johansen P, Nielsen JE, Holm IE; FReJA Consortium, Dickson DW, Rademakers R, Graff-Radford NR, Parisi JE, Petersen RC, Hatapaia KJ, White CL 3rd, Weiner MF, Geser F, Van Deerlin VM, Trojanowski JQ, Miller BL, Seeley WW, van der Zee J,
Kumar-Singh S, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bigio EH, Deng HX, Halliday GM, Kril JJ, Munoz DG, Mann DM, Pickering-Brown SM, Doodeman V, Adamson G, Ghazi-Noori S, Fisher EM, Holton JL, Revesz T, Rossor MN, Collinge J, Mead S, Isaacs AM (2010) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120(1):33–41

162. Valdmanis PN, Dupre N, Bouchard JP et al (2007) Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p. Arch Neurol 64:240–245

163. Vance C, Al-Chalabi A, Ruddy D et al (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129:868–876

164. Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181(1):37–41

165. Van Deerlin VM et al (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42(3):234–239

166. van der Zee J, Le Ber I, Maurer-Stroh S, Engelborghs S, Gijselinck I, Camuzaat A, Brouwers N, Vandenberghe R, Sleegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De Pooter T, Peeters K, Mattheijssens M, Vercelletto M, Van den Broeck M, Cruts M, De Deyn PP, Rousseau F, Zimprich A, Van Broeckhoven C (2007) Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 28(4):416

167. van der Zee J, Urwin H, Engelborghs S, Bruylant M, Vandenberghe R, Dermaut B, De Pooter T, Peeters K, Santens P, De Deyn PP, Fisher EM, Collinge J, Isaacs AM, Van Broeckhoven C (2008) CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet 17(2):313–322

168. van der Zee J, Pirici D, Van Langenhove T, Engelborghs S, Vandenberghe R, Hoffmann M, Pusswald G, Van den Broeck M, Peeters K, Mattheijssens M, Martin JJ, De Deyn PP, Cruts M, Haubenberger D, Kumar-Singh S, Zimprich A, Van Broeckhoven C (2009) Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 73(8):626–632

169. van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J, Mattheijssens M, Peeters K, Cras P, De Deyn PP, Cruts M, Van Broeckhoven C (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134(Pt 3):808–815

170. van Es MA, Veldink JH, Saris CG et al (2009) Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 41:1083–1087

171. Van Langenhove T, van der Zee J, Sleegers K, Engelborghs S, Vandenberghe R, Gijselinck I, Van den Broeck M, Mattheijssens M, Peeters K, De Deyn PP, Cruts M, Van Broeckhoven C (2010) Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74:366–371

172. van Langenhove T, van der Zee J, Van Broeckhoven C (2012) The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med (Epub ahead of print)

173. Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay-Falcone D, Elman L, McCluskey L, Lee VM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS (2012) Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol 121(3):373–380

174. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronik A, Whyte MP, Kimonis VE (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36(4):377–381

175. Weihl CC, Pestronik A, Kimonis VE (2009) Valosin-containing protein disease: inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia. Neuromuscul Disord 19(5):308–315

176. Weihl CC (2011) Valosin-containing protein associated frontotemporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Curr Alzheimer Res 8(3):252–260

177. Williams DR, Pittman AM, Resesz T, Lees AJ, de Silva R (2007) Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. Mov Disord 22(6):895–897

178. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, Ding A (2010) Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med 207(1):117–128